Cargando…
Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation
BACKGROUND: C‐terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts functional outcome. We aimed to evaluate agrin sub‐fragment...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799857/ https://www.ncbi.nlm.nih.gov/pubmed/27066319 http://dx.doi.org/10.1002/jcsm.12068 |
_version_ | 1782422408062304256 |
---|---|
author | Scherbakov, Nadja Knops, Michael Ebner, Nicole Valentova, Miroslava Sandek, Anja Grittner, Ulrike Dahinden, Pius Hettwer, Stefan Schefold, Jörg C von Haehling, Stephan Anker, Stefan D. Joebges, Michael Doehner, Wolfram |
author_facet | Scherbakov, Nadja Knops, Michael Ebner, Nicole Valentova, Miroslava Sandek, Anja Grittner, Ulrike Dahinden, Pius Hettwer, Stefan Schefold, Jörg C von Haehling, Stephan Anker, Stefan D. Joebges, Michael Doehner, Wolfram |
author_sort | Scherbakov, Nadja |
collection | PubMed |
description | BACKGROUND: C‐terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts functional outcome. We aimed to evaluate agrin sub‐fragment CAF22 as a marker of decreased muscle mass and physical performance in the early phase after acute stroke. METHODS: Patients with acute ischaemic or haemorrhagic stroke (n = 123, mean age 70 ± 11 y, body mass index BMI 27.0 ± 4.9 kg/m(2)) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI. Functional assessments were performed at begin (23 ± 17 days post stroke) and at the end of the structured rehabilitation programme (49 ± 18 days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assessment, and Barthel index. Body composition was assessed by bioelectrical impedance analysis (BIA). Serum levels of CAF22 were measured by ELISA. RESULTS: CAF22 levels were elevated in stroke patients at admission (134.3 ± 52.3 pM) and showed incomplete recovery until discharge (118.2 ± 42.7 pM) compared to healthy controls (95.7 ± 31.8 pM, p < 0.001). Simple regression analyses revealed an association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived measure of the muscle cellular integrity. Improvement of the handgrip strength of the paretic arm during rehabilitation was independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during the rehabilitation. CONCLUSIONS: CAF22 serum profiles showed a dynamic elevation and recovery in the subacute phase after acute stroke. Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after stroke. |
format | Online Article Text |
id | pubmed-4799857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47998572016-04-08 Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation Scherbakov, Nadja Knops, Michael Ebner, Nicole Valentova, Miroslava Sandek, Anja Grittner, Ulrike Dahinden, Pius Hettwer, Stefan Schefold, Jörg C von Haehling, Stephan Anker, Stefan D. Joebges, Michael Doehner, Wolfram J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: C‐terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts functional outcome. We aimed to evaluate agrin sub‐fragment CAF22 as a marker of decreased muscle mass and physical performance in the early phase after acute stroke. METHODS: Patients with acute ischaemic or haemorrhagic stroke (n = 123, mean age 70 ± 11 y, body mass index BMI 27.0 ± 4.9 kg/m(2)) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI. Functional assessments were performed at begin (23 ± 17 days post stroke) and at the end of the structured rehabilitation programme (49 ± 18 days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assessment, and Barthel index. Body composition was assessed by bioelectrical impedance analysis (BIA). Serum levels of CAF22 were measured by ELISA. RESULTS: CAF22 levels were elevated in stroke patients at admission (134.3 ± 52.3 pM) and showed incomplete recovery until discharge (118.2 ± 42.7 pM) compared to healthy controls (95.7 ± 31.8 pM, p < 0.001). Simple regression analyses revealed an association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived measure of the muscle cellular integrity. Improvement of the handgrip strength of the paretic arm during rehabilitation was independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during the rehabilitation. CONCLUSIONS: CAF22 serum profiles showed a dynamic elevation and recovery in the subacute phase after acute stroke. Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after stroke. John Wiley and Sons Inc. 2015-10-27 2016-03 /pmc/articles/PMC4799857/ /pubmed/27066319 http://dx.doi.org/10.1002/jcsm.12068 Text en © 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Scherbakov, Nadja Knops, Michael Ebner, Nicole Valentova, Miroslava Sandek, Anja Grittner, Ulrike Dahinden, Pius Hettwer, Stefan Schefold, Jörg C von Haehling, Stephan Anker, Stefan D. Joebges, Michael Doehner, Wolfram Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
title | Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
title_full | Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
title_fullStr | Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
title_full_unstemmed | Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
title_short | Evaluation of C‐terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
title_sort | evaluation of c‐terminal agrin fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799857/ https://www.ncbi.nlm.nih.gov/pubmed/27066319 http://dx.doi.org/10.1002/jcsm.12068 |
work_keys_str_mv | AT scherbakovnadja evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT knopsmichael evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT ebnernicole evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT valentovamiroslava evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT sandekanja evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT grittnerulrike evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT dahindenpius evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT hettwerstefan evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT schefoldjorgc evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT vonhaehlingstephan evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT ankerstefand evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT joebgesmichael evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation AT doehnerwolfram evaluationofcterminalagrinfragmentasamarkerofmusclewastinginpatientsafteracutestrokeduringearlyrehabilitation |